Hong-Tao Li
Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hong-Tao Li as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:15 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06562673 · Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in OsteosarcomaShanghai 6th People's Hospital · completed · Osteosarcoma, Bone Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in osteosarcoma, ranked by citations from NIH iCite, fetched 2026-11-12 10:15 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001.Clin Cancer Res · 202316 citationsRCR 1.4
- Significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on GLS1 expression.Eur Rev Med Pharmacol Sci · 201814 citationsRCR 0.5
- [Fast neutron treatment of osteosarcoma].Zhonghua Zhong Liu Za Zhi · 19941 citationsRCR 0.1